Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Actinium Pharmaceuticals, Inc. ('Actinium' or the 'Company') (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024, inclusive (the 'Class Period'). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.
The Complaint alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that the Defendants failed to disclose to investors that: (1) the Company's data from Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
According to the Complaint, the truth began to reach the market on August 5, 2024, when the Company announced that 'the analyses from the Sierra Trial do not adequately support a BLA filing for Iomab-B and requires an additional clinical study,' and Actinium's stock price suffered significant declines, harming investors.
Investors who purchased or otherwise acquired shares of Actinium should contact the Firm prior to the May 26, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
27 minutes ago
- Associated Press
UPDATE - Sono Group N.V. Reschedules Participation in Emerging Growth Conference to Tuesday, June 17, 2025
Munich, June 06, 2025 (GLOBE NEWSWIRE) -- The solar technology company Sono Group N.V. ( OTCQB: SEVCF ) (hereafter referred to as 'Sono Group' or 'Sono', parent company to Sono Motors GmbH or 'Sono Motors') today announced that its previously scheduled presentation at the Emerging Growth Conference on May 21, 2025, has been moved to the next event in the series. The Company will now present on Tuesday, June 17, 2025, from 1:45 PM to 2:15 PM Eastern Time. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Managing Director and CEO, George O'Leary, in real time. Mr. O'Leary will provide an update on the Company's strategy and recent developments, including the newly announced projects, the first quarter 2025 results published earlier this month, and key partnerships. Mr. O'Leary will give a presentation and may subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. O'Leary will do his best to get through as many of them as possible. Please register here to ensure you are able to attend the conference and receive any updates that are released. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on the Company's investor relations website. In addition to the Emerging Growth Conference, Sono also confirms George O'Leary's participation in the upcoming Webull EV Webinar, taking place on Tuesday, June 24, 2025. Further details, including the agenda and registration link, will be provided closer to the date. 'Our recently published Q1 results demonstrate continued progress in our core business,' said George O'Leary. 'At the June 17 conference and at Webull EV Webinar on June 24, I look forward to sharing more about our momentum in the Sono business plans, our expanding partnerships, our new opportunities and an update on our planned uplisting to Nasdaq.' END ABOUT SONO GROUP N.V. Sono Group N.V. ( OTCQB: SEVCF ) and its wholly owned subsidiary Sono Motors GmbH are on a pioneering mission to accelerate the revolution of mobility by making every commercial vehicle solar. Our disruptive solar technology has been developed to enable seamless integration into all types of commercial vehicles to reduce the impact of CO2 emissions and pave the way for climate-friendly mobility. For more information about Sono Group N.V., Sono Motors, and their solar solutions, visit and Follow us on social media: LinkedIn, Facebook, BlueSky, Truth Social, and X. FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements. The words 'expect', 'anticipate', 'intend', 'plan', 'estimate', 'aim', 'forecast', 'project', 'target', 'will' and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the intentions, beliefs, or current expectations of the Company and its subsidiary Sono Motors GmbH (together, the 'companies'). Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and could cause the companies' actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and assumptions include, but are not limited to, risks, uncertainties and assumptions with respect to: the Company's ability to uplist to the Nasdaq Capital Market, including meeting the initial listing requirements; the Company's ability to satisfy the conditions precedent set forth in its recent securities purchase agreement ('Securities Purchase Agreement') and exchange agreement ('Exchange Agreement') entered into with YA II PN, Ltd. ('Yorkville'); the timing of closing the transactions contemplated by the Securities Purchase Agreement and the Exchange Agreement; the impact of the transactions contemplated by the Exchange Agreement and Securities Purchase Agreement on the Company's operating results; our ability to maintain relationships with creditors, suppliers, service providers, customers, employees and other third parties in light of the performance and credit risks associated with our constrained liquidity position and capital structure; our ability to comply with OTCQB continuing standards; our ability to achieve our stated goals; our strategies, plan, objectives and goals, including, among others, the successful implementation and management of the pivot of our business to exclusively retrofitting and integrating our solar technology onto third party vehicles; our ability to raise the additional funding required beyond the investment from Yorkville to further develop and commercialize our solar technology and business as well as to continue as a going concern. For additional information concerning some of the risks, uncertainties and assumptions that could affect our forward-looking statements, please refer to our filings with the U.S. Securities and Exchange Commission ('SEC'), including our Annual Report on Form 20-F for the year ended December 31, 2023, which are accessible on the SEC's website at and on our website at Many of these risks and uncertainties relate to factors that are beyond our ability to control or estimate precisely, such as the actions of courts, regulatory authorities and other factors. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the Company assumes no obligation to update any such forward-looking statements. CONTACT SONO GROUP N.V. Press: [email protected] | Investors: [email protected] | LinkedIn:
Associated Press
27 minutes ago
- Associated Press
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jun 6, 2025-- Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo 1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data 1. Specifically, 76.3% of patients treated with sibeprenlimab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group. 1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenlimab compared to 5.4% treated with placebo. Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 2. Sibeprenlimab is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation 3,4,5,6. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home. 'We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials,' said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. 'Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease.' The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be completed in early 2026. Further prespecified and exploratory analyses of the data will be conducted to determine the full potential of sibeprenlimab for the treatment of IgAN 1. 'The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo. These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date. The study enrolled a diverse patient population reflective of the disease epidemiology,' said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham. 'The safety data emerging from VISIONARY is reassuring and adds to our existing knowledge about sibeprenlimab's safety profile from prior programs. This is very exciting news for patients and adds a therapeutic option with a novel mechanism of action potentially targeting the immunologic pathogenesis of IgAN.' About the VISIONARY Study The VISIONARY study is the largest IgAN trial to date, and is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 510 adult patients with IgAN who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo 1. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over ~24 months 1. About Sibeprenlimab Sibeprenlimab (formerly VIS649) was designed and engineered by Visterra, Inc., a wholly owned subsidiary of Otsuka. Pre-clinical and early-stage trials of sibeprenlimab were also conducted by Visterra. Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit process. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Decreased immune complex formation should result in diminished deposition in the kidney, and reduced proteinuria and kidney inflammation 8. By reducing the production of Gd-IgA1, sibeprenlimab may help slow kidney damage and progression toward ESKD 3,4,5,6. By inhibiting APRIL, sibeprenlimab may help address one of the IgAN-specific drivers for nephron loss. About IgAN and APRIL IgAN is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to ESKD over the lifetime of most patients 9,10,11. IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys. IgAN can lead to progressive loss of kidney function and, eventually, ESKD, imposing a significant burden on patients 10. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition. Continued research in the disease remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients 5. APRIL, a cytokine in the tumor necrosis factor (TNF) family, is integral to the pathogenesis and progression of IgAN. It promotes the survival and class switching of B cells to produce IgA, particularly the pathogenic galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes in the kidneys 5. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a 'big venture' company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024. All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at About Visterra Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision biologics-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting kidney diseases, immunologically-driven diseases and infectious diseases. Visterra is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, visit References View source version on CONTACT: Contacts for MediaOtsuka in the Murphy Corporate Communications Otsuka America Pharmaceutical, Inc. [email protected]+1 609 249 7262Otsuka in JapanJeffrey Gilbert Leader, Pharmaceutical PR Otsuka Pharmaceutical Co., Ltd. [email protected]+81 3 6361 7379 KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC NEW JERSEY INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS OTHER HEALTH SOURCE: Otsuka Pharmaceutical Co., Ltd. Copyright Business Wire 2025. PUB: 06/06/2025 06:00 AM/DISC: 06/06/2025 05:58 AM
Yahoo
27 minutes ago
- Yahoo
American Vanguard Reports First Quarter 2025 Results
Substantially Reduced Operating Expenses Materially Decreased Net Working Capital Consumption Industry In the Early Innings of a Recovery NEWPORT BEACH, Calif., June 06, 2025--(BUSINESS WIRE)--American Vanguard® Corporation (NYSE: AVD), a diversified specialty and agricultural products company that develops, manufactures, and markets solutions for crop protection and nutrition, turf and ornamental management and commercial pest control, today reported financial results for the first quarter ended March 31, 2025. Financial and Operational Highlights – First Quarter 2025 versus First Quarter 2024: Net sales of $115.8 million v. $135.1 million; Adjusted EBITDA1 of $3.0 million v. $15.5 million; EPS of $(0.30) v. $0.06 Other Operational Highlights: Reduced net working capital by $85M year-over-year While operating expenses decreased by 5% on a GAAP basis, as compared to the year ago period, they decreased by 14% excluding transformation expenses and a non-recurring item CEO Douglas A. Kaye III stated, "The first quarter of 2025 presented a challenging environment for suppliers to the global agricultural sector, continuing trends that we have experienced over the past 18-24 months. Against a backdrop of global economic uncertainty and generally high interest rates, customers focused on managing working capital by reducing inventory and limiting procurement to a just-in-time basis. In the face of these conditions, our results for the quarter declined, as compared to last year. While I am pleased with the progress we have made, if market conditions do not improve, we will enact further cost reduction initiatives over the coming quarters. We have made meaningful improvement to our cost structure, but much of that progress is currently being overshadowed in our financial results so far this year by the continued weakness in the agricultural environment." Mr. Kaye continued, "The environment is beginning to improve in the second quarter, and, like most industry participants in the agricultural chemical industry, we expect the second half of 2025 to be both seasonally stronger and to benefit from improving customer order rates. We expect to realize the benefit of commercial and operational improvements that are either completed or are well underway. As we continue to transform and simplify this business, future margins will improve, and further margin enhancement in 2026 and beyond is the target." David T. Johnson, Vice President, CFO and Treasurer, stated "While the industry recovers from its cyclical downturn, the team has made meaningful improvement to the cost structure. We are pleased with the results from our initial efforts to contain costs and will continue to keep a tight rein on non-essential costs for the foreseeable future. In addition to minimizing operating expenses, we have made significant improvements to our balance sheet. We ended the quarter with total debt of $167 million, which was down from $187 million the prior year. Net working capital decreased to $153 million versus $238 million a year ago. We will continue to focus on strengthening our balance sheet and positioning American Vanguard for a return to growth." Mr. Kaye concluded, "I believe that simplifying many of the things we do will allow us to better understand what is important and to deliver against high priority tasks. My message across the organization in this regard is straightforward – SIMPLIFY, PRIORITIZE and DELIVER. If we embrace this mantra, I believe that we can reaffirm American Vanguard's position as a trusted provider of proven agricultural and environmental solutions." 1 Adjusted earnings before interest, taxes, depreciation, and amortization. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company's competitors) may define adjusted EBITDA differently. Earnings Conference CallThe company will be hosting an earnings conference call at 9 am Eastern Time on June 6, 2025. The conference call can be accessed through the following link: A replay can also be accessed through the website. In addition, the company plans to post on the Investor Relations section of the company's website a presentation that should be read in connection with this earnings release. About American VanguardAmerican Vanguard Corporation is a diversified specialty and agriculture products company that develops and markets products for crop protection and management, turf and ornamentals management, and public and animal health. Over the past 20 years, through product and business acquisitions, the Company has significantly expanded its operations and now has more than 1,000 product registrations worldwide. To learn more about the Company, please reference The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release the matters set forth in this press release include forward-looking statements. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often use words such as "believe," "expect," "anticipate," "intend," "estimate," "project," "outlook," "forecast," "target," "trend," "plan," "goal," or other words of comparable meaning or future-tense or conditional verbs such as "may," "will," "should," "would," or "could." These forward-looking statements are based on the current expectations and estimates by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include risks detailed from time-to-time in the Company's SEC reports and filings. All forward-looking statements, if any, in this release represent the Company's judgment as of the date of this release. The company disclaims any intent or obligation to update these forward-looking statements. AMERICAN VANGUARD CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except share data)(Unaudited) ASSETS March 31,2025 December 31,2024 Current assets: Cash $ 11,805 $ 12,514 Receivables: Trade, net of allowance for credit losses of $10,321 and $9,190, respectively 159,559 169,743 Other 8,155 4,699 Total receivables, net 167,714 174,442 Inventories 184,596 179,292 Prepaid expenses 8,507 7,615 Income taxes receivable 5,226 5,030 Total current assets 377,848 378,893 Property, plant and equipment, net 57,016 58,169 Operating lease right-of-use assets, net 18,430 19,735 Intangible assets, net 147,668 150,497 Goodwill 20,291 19,701 Deferred income tax assets 1,331 1,242 Other assets 9,004 8,484 Total assets $ 631,588 $ 636,721 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 93,920 $ 69,159 Customer prepayments 24,460 52,675 Accrued program costs 70,319 69,449 Accrued expenses and other payables 17,119 31,989 Operating lease liabilities, current 5,986 6,136 Income taxes payable 1,261 2,942 Total current liabilities 213,065 232,350 Long-term debt 167,498 147,332 Operating lease liabilities, long-term 13,074 14,339 Deferred income tax liabilities 8,924 7,989 Other liabilities 1,673 1,601 Total liabilities 404,234 403,611 Commitments and contingent liabilities (Note 13) Stockholders' equity: Preferred stock, $0.10 par value per share; authorized 400,000 shares; none issued — — Common stock, $0.10 par value per share; authorized 40,000,000 shares; issued 34,850,030 shares at March 31, 2025 and 34,794,548 shares at December 31, 2024 3,485 3,479 Additional paid-in capital 115,554 114,679 Accumulated other comprehensive loss (16,904 ) (18,729 ) Retained earnings 196,420 204,882 298,555 304,311 Less treasury stock at cost, 5,915,182 shares at March 31, 2025 and December 31, 2024 (71,201 ) (71,201 ) Total stockholders' equity 227,354 233,110 Total liabilities and stockholders' equity $ 631,588 $ 636,721 AMERICAN VANGUARD CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)(Unaudited) For the three monthsended March 31 2025 2024 Net sales $ 115,800 $ 135,143 Cost of sales (85,609 ) (92,725 ) Gross profit 30,191 42,418 Operating expenses Selling, general and administrative (26,566 ) (29,469 ) Research, product development and regulatory (5,682 ) (5,706 ) Transformation (2,253 ) (1,152 ) Operating (loss) income (4,310 ) 6,091 Change in fair value of an equity investment — 638 Interest expense, net (3,765 ) (3,693 ) (Loss) income before provision for income taxes (8,075 ) 3,036 Income tax expense (387 ) (1,484 ) Net (loss) income $ (8,462 ) $ 1,552 Net (loss) income per common share—basic $ (0.30 ) $ 0.06 Net (loss) income per common share—assuming dilution $ (0.30 ) $ 0.06 Weighted average shares outstanding—basic 28,271 27,844 Weighted average shares outstanding—assuming dilution 28,271 28,128 AMERICAN VANGUARD CORPORATION AND SUBSIDIARIESANALYSIS OF SALES(In thousands), (Unaudited) For the three months endedMarch 31, 2025 2024 Change % Change Net sales: U.S. crop $ 57,176 $ 67,257 $ (10,081 ) -15 % U.S. non-crop 15,601 17,768 (2,167 ) -12 % Total U.S. 72,777 85,025 (12,248 ) -14 % International 43,023 50,118 (7,095 ) -14 % Total net sales $ 115,800 $ 135,143 $ (19,343 ) -14 % Total cost of sales $ (85,609 ) $ (92,725 ) $ 7,116 -8 % Total gross profit $ 30,191 $ 42,418 $ (12,227 ) -29 % Total gross margin 26 % 31 % AMERICAN VANGUARD CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited) For the three monthsended March 31 2025 2024 Cash flows from operating activities: Net (loss) income $ (8,462 ) $ 1,552 Adjustments to reconcile net (loss) income to net cash used in operating activities: Depreciation and amortization of property, plant and equipment and intangible assets 4,744 5,441 Amortization of other long-term assets 5 189 Provision for bad debts 1,056 700 Stock-based compensation 559 2,005 Change in deferred income taxes 1,348 (1,025 ) Change in liabilities for uncertain tax positions or unrecognized tax benefits 90 35 Change in equity investment fair value — (638 ) Other 126 (5 ) Foreign currency transaction gains (99 ) (373 ) Changes in assets and liabilities associated with operations: Decrease (increase) in net receivables 6,892 (5,579 ) Increase in inventories (4,721 ) (9,353 ) Increase in prepaid expenses and other assets (856 ) (1,466 ) Change in income tax receivable and payable, net (1,885 ) 1,014 Increase in accounts payable 22,966 2,366 Decrease in customer prepayments (28,215 ) (37,037 ) Increase in accrued program costs 837 6,399 Decrease in other payables and accrued expenses (14,961 ) (332 ) Net cash used in operating activities (20,576 ) (36,107 ) Cash flows from investing activities: Capital expenditures (431 ) (3,565 ) Proceeds from disposal of property, plant and equipment 12 23 Intangible assets (27 ) (25 ) Net cash used in investing activities (446 ) (3,567 ) Cash flows from financing activities: Payments under line of credit agreement (89,098 ) (35,346 ) Borrowings under line of credit agreement 109,265 77,146 Payment of deferred loan fees (687 ) — Net receipt from the issuance of common stock under ESPP 332 430 Net payment from common stock purchased for tax withholding (11 ) (14 ) Payment of cash dividends — (834 ) Net cash provided by financing activities 19,801 41,382 Net (decrease) increase in cash (1,221 ) 1,708 Effect of exchange rate changes on cash and cash equivalents 512 585 Cash at beginning of period 12,514 11,416 Cash at end of period $ 11,805 $ 13,709 AMERICAN VANGUARD CORPORATION AND SUBSIDIARIESRECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA(Unaudited) Reconciliation of Net Income to EBITDA March 31, 2025 March 31, 2024 Net income, as reported $ (8,462 ) $ 1,552 Provision for income taxes 387 1,484 Interest expense, net 3,765 3,693 Depreciation and amortization 4,749 5,630 Stock compensation 559 2,005 Dacthal returns (216 ) — Transformation costs 2,191 1,152 Adjusted EBITDA2 $ 2,973 $ 15,516 2 Adjusted earnings before interest, taxes, depreciation, and amortization. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from adjusted EBITDA are detailed in the above reconciliation. Other companies (including the Company's competitors) may define adjusted EBITDA differently. View source version on Contacts Company Contact American Vanguard CorporationAnthony Young, Director of Investor Relationsanthonyy@ (949) 221-6119Investor Representative Alpha IR GroupRobert (929) 266-6315 Sign in to access your portfolio
